Browsing Tag
remestemcel-L
2 posts
Mesoblast revenue jumps sevenfold to $120m as Ryoncil turns cell therapy into a commercial business
Mesoblast generated $120.3 million of FY26 revenue, including $115.2 million from Ryoncil, while narrowing its loss 44% and advancing adult GVHD, Duchenne, back pain and heart-failure programmes.
Mesoblast (ASX: MSB) ramps up GVHD play with record Ryoncil revenue and fresh $125m credit line
Ryoncil sales surged 60 percent for Mesoblast in Q4. Read how its $125M refinancing plan could reshape capital efficiency and future cell therapy expansion.